VERAXA Biotech Unveils BiTAC-ADC Platform Data, Targets Solid Tumors

VERAXA Biotech (NASDAQ: VRXA) has announced new in vitro proof-of-concept data for its novel BiTAC(TM)-ADC technology platform, designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The data demonstrated that BiTAC-ADCs can distinguish between breast cancer and healthy cells, achieving dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity via separately delivered, systemically inactive precursor components. This breakthrough positions VERAXA to address key challenges in oncology, such as off-target effects, and complements its existing BiTAC-TCE platform, offering two differentiated cancer therapy approaches for solid tumors.

Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. The company, founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. The full press release is available at https://ibn.fm/QiPhH, and updates can be found in the company’s newsroom at https://ibn.fm/VRXA.

VERAXA's BiTAC-ADC platform represents a significant step toward safer, more effective cancer therapies. By combining tumor-specific activation with the potency of ADCs, the technology could reduce systemic toxicity and improve patient outcomes. The company's dual-platform strategy (BiTAC-ADC and BiTAC-TCE) provides versatility across multiple solid tumor indications, potentially expanding treatment options for patients with limited alternatives. As VERAXA seeks partnerships at BIO 2026, the industry will watch closely to see how these innovative technologies translate into clinical success.